KCT0006015Completed未知
A 12-week, randomized, double-blind, placebo-controlled human trial to evaluate the efficacy and safety of Chitooligosaccharide(GO2KA1) on decrease of body fat
Wonkwang University. Iksan Korean Medicine Hospital0 sites80 target enrollmentStarted: TBDLast updated:
Trial Snapshot
- Phase
- 未知
- Status
- Completed
- Sponsor
- Enrollment
- 80
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional Study
Eligibility Criteria
- Ages
- 19(Year) to 65(Year) (—)
- Sex
- All
Inclusion Criteria
- •1) 25 = BMI = 34.9 kg/m2 or 25%(male), 30%(female) =body fat percentage
- •2) Participants who have fully understood information provided about the study, voluntarily decided to participate, and agreed to comply with precautions
Exclusion Criteria
- •1) Participants who have had a weight change of 10% of more within the 3 months prior to the screening examination.
- •2) Participants with a clinically significant disease requiring treatment (i.e., acute or chronic cardiovascular system, endocrine system, immune system, respiratory system, kidney and urinary system, neuropsychiatric system, musculoskeletal inflammation, inflammatory disease, blood and tumor disease, gastrointestinal disease, etc.)
- •3) Fasteners
- •4) Participants with a history of antipsychotic medication use within 3 months prior to the screening examination.
- •5) Participants who have participated in other interventional clinical trials within 3 months prior to the screening examination, or plan to participate in other interventional clinical trials.
- •6) Participants who are judged ineligible to participate in the trial by the principal investigator for other reasons, including laboratory test outcomes.
Investigators
Similar Trials
Recruiting
Unknown
A human trial of SMSP8118 on improvement of Liver functioDiseases of the digestive systemKCT0009369Jeonbuk National University Hospital80
Active, not recruiting
Not Applicable
A 12-week, randomized, double-blind, placebo-controlled, parallel group, multicenter study to evaluate the efficacy, safety and tolerability of darifenacin (7.5 mg o.d. with voluntary up-titration to 15 mg o.d.) in patients aged = 65 years with overactive bladder - Not applicableOveractive bladder (OAB)EUCTR2004-002894-21-DEovartis Pharma Services AG399
Recruiting
Unknown
Clinical trial to evaluate the effectiveness and safety of EEFE on cognitive function improvementKCT0009469Ewha Womens University80
Recruiting
Not Applicable
A 12-week, randomized, double-blind, placebo-controlled human application trial to evaluate the efficacy and safety of ACP_01 on skin wrinkle improvement and moisturizingKCT0007720Daehan Chemtech Co., Ltd100
Recruiting
Not Applicable
Evalution of the Effectiveness and Safety of ChondroT on the Knee ArthritisKCT0007997Dongshin University Mokpo Oriental Hospital160